Lilly ends Phase III development of gamma secretase inhibitor for Alzheimer's

Hopes for a therapy that slows or halts the progression of Alzheimer's disease have been dashed again after Lilly said that it would cease development of its gamma secretase inhibitor semagacestat, after an interim analysis from two ongoing pivotal Phase III studies showed it did not slow disease progression in those with mild-to-moderate disease.